more info

Start date: 1 April 2017

End date: 31 May 2027

Number of projects: 8

Total budget: 45 911 010,20 €

EU contribution: 35 140 973,07 €

Website: n/a

Country:

European Commission Flag

Explore more: n/a

funds

ERDF: 35 140 973,07 €

CAPTOR THERAPEUTICS S.A.

PROGRAMMING PERIOD

1 - 8 of 8

PROJECT

TOTAL BUDGET

EU CONTRIBUTION

FUND

Use of targeted protein degradation technology in the treatment of psoriasis and rheumatoid arthritis.

8 254 208,80 €

6 570 758,96 €

ERDF

Induction of apoptosis using small molecular compounds as therapeutic intervention in cancer

8 264 522,50 €

6 528 743,50 €

ERDF

Development and development of a candidate for the treatment of hepatocellular cancer, which allows the elimination of cancer stem cells, through induced degradation of oncogenic transcription agent.

8 089 278,31 €

6 437 728,64 €

ERDF

Development and development of the first in the class of a drug candidate, a small molecular degrader, in the treatment of colorectal cancer.

7 122 915,76 €

5 671 024,16 €

ERDF

Development of new anti-inflammatory drugs specifically degrading cell surface receptors

7 111 171,68 €

5 406 338,85 €

ERDF

Development of an integrated technology platform in the field of targeted protein degradation and its implementation on the pharmaceutical market

2 232 031,77 €

1 708 035,27 €

ERDF

Development and development of a drug candidate for the treatment of hepatocellular cancer, allowing the elimination of cancer stem cells through induced degradation of the oncogenic transcription factor – Phase II

2 964 330,82 €

1 623 877,91 €

ERDF

Induction of apoptosis using small molecule chemicals as a therapeutic intervention in cancer – Phase II

1 872 550,56 €

1 194 465,78 €

ERDF